Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

83%

5 trials in Phase 3/4

Results Transparency

100%

6 of 6 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

Phase 3

5(83.3%)

Phase 2

1(16.7%)

6Total

Phase 3(5)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT00981682Phase 3Completed

Long Term Safety Assessment of SER120 in Patients With Nocturia

Role: lead

NCT01259128Phase 3Completed

Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray in Elderly Patients With Nocturia

Role: lead

NCT01900704Phase 3Completed

Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia - DB4

Role: lead

NCT00937378Phase 3Completed

Treatment of Patients With Nocturia (Non-PK Study)

Role: lead

NCT01357356Phase 2Completed

Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia

Role: lead

NCT00937859Phase 3Completed

Treatment of Patients With Nocturia

Role: lead

All 6 trials loaded